Navigation Links
Gamida Cell and Cellerix Partner on Feasibility Study
Date:10/21/2009

JERUSALEM and MADRID, October 21 /PRNewswire/ -- Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

Gamida Cell is developing a series of technologies to expand, ex vivo, populations of stem/progenitor cells that display increased in vivo homing and engraftment activities. The company's lead product, StemEx(R), comprised of expanded populations of adult stem cells derived from umbilical cord blood (UCB), is used today as an experimental treatment for blood cancers like leukemia and lymphoma. The Company anticipates StemEx(R) will reach the market in 2011.

Cellerix is developing a new generation of cell-based medicines using expanded adult stem cells (eASCs) obtained from adipose tissue. The Company is also very active developing its allogeneic eASCs platform as 2nd generation products through its Cx611 program for high potential markets. eASCs are a natural medicine with the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a potential revolution in the treatment of some diseases that cannot satisfactorily be cured at present.

"Gamida Cell is enthusiastic about working with Cellerix, a world class company and an industry leader," said Dr. Yael Margolin, president and CEO of Gamida Cell. "Gamida Cell's technologies have demonstrated to improve in vivo functionality of ex-vivo expanded hematopoietic stem cells. This collaboration seeks to evaluate the feasibility of improving clinical efficacy of ex vivo expanded adult stem cells obtained from adipose tissue by means of increasing homing and retention following infusion. The results of this study could lead to an entirely new understanding of the widespread application of our various technologies and expand the number of possibilities for Gamida Cell
'/>"/>

SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
11. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... PharmaBoardroom,s new report, , Healthcare and Life ... free download , digs deep into this vibrant market, speaking ... today. One area where Algeria ... homegrown pharmaceutical manufacturing base, even if the government,s ambitious target ... A cursory comparison with neighboring Morocco ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, ... the University of Calgary in conjunction with co-authors from ... further validates the company,s ongoing clinical research using dermal ... pattern baldness. The paper entitled " Hair ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... Experience to the Leader in ... Cellular Bioenergetic Profiling, N. BILLERICA, ... for real-time measurement of cellular,bioenergetics in microplates, announced today that ... company,s Board of,Directors. In this position, Keegan will apply his ...
... Cadus Corporation (OTC,Bulletin Board: KDUS) announced today financial results for ... for the second quarter of 2007 and for the same ... was $218,960, compared,to net income of $75,387 for the same ... quarter of 2007 was $0.02, compared to basic net,income per ...
... a Phase II study of R1507 ... for the Treatment of Sarcoma, ... its partner, Roche has initiated a Phase II,clinical study of R1507 ... created by Genmab under the company,s,agreement with Roche and initiation of ...
Cached Biology Technology:Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2Cadus Reports Second Quarter 2007 Results 2Cadus Reports Second Quarter 2007 Results 3Cadus Reports Second Quarter 2007 Results 4Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma 2
(Date:12/22/2014)... DENVER , Dec. 22, 2014  The ... for the biometrics industry as Acuity Market Intelligence ... biometrics may finally be open. Acuity forecasts that ... mobile devices that incorporate biometrics will drive a ... 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... North America Perimeter Security Systems Market" report to ... The North American perimeter security market is ... 2014 to 2019. Although the U.S. market holds a ... is expected to grow at a higher CAGR ...
(Date:12/19/2014)... 18, 2014   LaunchKey , the first decentralized ... and Internet of Things era, today announced the close ... round was led by Metamorphic Ventures with participation from ... VegasTechFund, and others.  LaunchKey has raised $4 million to ... its team and bring LaunchKey to market in 2015. ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... announced today that they have entered into ... its proprietary photocleavable biotin reagent for the ... The biggest constraint on successful ... is achieving sufficient sensitivity. SomaLogic,s innovative SOMAmer ...
... 29, 2011) The future brightened for organic chemistry when ... attach organic molecules to pristine graphene, making the miracle material ... lab of chemist James Tour, building upon a set of ... method that turned what was a single-atom-thick sheet of carbon ...
... A team of scientists from Worcester Polytechnic Institute ... Life Sciences and Bioengineering Center, have regenerated functional muscle ... clinical therapy to treat people who suffer major muscle ... coax mature human muscle cells into a stem cell-like ...
Cached Biology News:Graphene lights up with new possibilities 2Graphene lights up with new possibilities 3Body rebuilding: Researchers regenerate muscle in mice 2Body rebuilding: Researchers regenerate muscle in mice 3
... stain has bright fluorescence when bound to dsDNA ... for detecting dsDNA in gels using laser scanners ... nucleic acid stain has also found uses ... bandshift assays. A 500 µL unit size (S-7563) ...
... 1) Persistent Analysis Environment 2) ... Histograms, etc. 3) Software Compensation 4) ... Advanced Kinetics Platform 7) Intelligent batch generation ... contour smoothing 9) Single drag-and-drop operations to ...
Synonym: modified Grace's Insect medium...
Eagle's Ham's amino acids; EHAA...
Biology Products: